Key terms

About PCRX

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest PCRX news

Mar 13 7:24am ET Pacira granted RMAT designation for PCRX-201 Mar 07 4:50am ET Pacira assumed with an Overweight at JPMorgan Mar 03 12:27pm ET Pacira price target lowered to $40 from $50 at Barclays Mar 03 10:15am ET Buy Rating Affirmed for Pacira Pharmaceuticals Amid Strategic Growth Initiatives and Management Restructuring Mar 01 9:30am ET Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and Pacira Pharmaceuticals (PCRX) Mar 01 7:35am ET Truist Financial Keeps Their Buy Rating on Pacira Pharmaceuticals (PCRX) Mar 01 7:26am ET RBC Capital Sticks to Its Buy Rating for Pacira Pharmaceuticals (PCRX) Feb 29 4:25pm ET Strong Buy Rating for Pacira Pharmaceuticals Amid Favorable NOPAIN Act Implications and Strategic Growth Initiatives Feb 29 8:12am ET Pacira Pharmaceuticals CFO Transition and Financial Update Feb 29 8:04am ET Pacira reports Q4 EPS 89c, consensus 88c Feb 15 8:39am ET Pacira announces publication of study of EXPAREL Feb 07 3:16pm ET Buy Rating for Pacira Pharmaceuticals: Strategic Partnerships and Market Opportunities Fuel Growth Outlook Feb 07 8:16am ET Pacira awarded Brand Pharmaceuticals agreement with Premier Jan 29 5:07am ET Barclays Sticks to Its Buy Rating for Pacira Pharmaceuticals (PCRX) Jan 26 6:20am ET Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Repare Therapeutics (RPTX) Jan 26 6:06am ET Pacira named a top pick for 2024 at H.C. Wainwright Jan 07 9:30pm ET Analysts Are Bullish on These Healthcare Stocks: Arvinas Holding Company (ARVN), Pacira Pharmaceuticals (PCRX) Jan 05 8:46pm ET RBC Capital Sticks to Its Buy Rating for Pacira Pharmaceuticals (PCRX) Jan 05 6:50am ET Analysts Are Bullish on Top Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Phathom Pharmaceuticals (PHAT) Jan 05 6:40am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Jan 04 5:02pm ET Pacira reports preliminary FY23 revenue $675M, consensus $677.3M Dec 21 7:34am ET Pacira appoints Frank Lee as CEO Dec 20 5:22am ET Pacira initiated with an Outperform at Raymond James

No recent news articles are available for PCRX

No recent press releases are available for PCRX

PCRX Financials

1-year income & revenue

Key terms

PCRX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

PCRX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms